Cadila gets USFDA nod for Doxycycline Hyclate Delayed-Release Tablets

The group has also received tentative approval for Febuxostat Tablets (US RLD-Uloric), 40 mg and 80 mg.

Dec 24, 2018 06:12 IST India Infoline News Service

Cadila Healthcare
Zydus Cadila, in a filing to the exchanges on Monday, informed that it has received approval from the USFDA to market Doxycycline Hyclate Delayed-Release Tablets USP (US RLD-Doryx) in the strengths of 75mg, 100mg, and 150mg.

The group will manufacture the tablets at its formulations manufacturing facility at SEZ, Ahmedabad. "This medication is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria," the company said in a press note to the exchanges on Monday.

Further, "the group also received tentative approval for Febuxostat Tablets (US RLD-Uloric), 40 mg and 80 mg, which will be manufactured facility at Moraiya, Ahmedabad," Zydus group added.

With this, Zydus now has 241 approvals and has, so far, filed over 340 ANDAs since the commencement of the filing process in FY04, the company said.

Cadila Healthcare Ltd share price is currently trading flat on the BSE.

The scrip opened at Rs343.80 and has touched a high and low of Rs344.20 and Rs340.60, respectively. So far, 2,64,854 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs35,017.12cr.

Related Story